Metabolomic profile of cancer stem cell-derived exosomes from patients with malignant melanoma
MetadatosMostrar el registro completo del ítem
AutorPalacios Ferrer, José Luis; García Ortega, María Belén; García Chaves, María Ángel; Díaz, Caridad; Boulaiz Tassi, Houria; Valdivia, Javier; Jurado, José Miguel; Almazán Fernández, Francisco Manuel; Arias Santiago, Salvador; Amezcua, Víctor; Peinado, Héctor; Vicente, Francisca; Pérez del Palacio, José; Marchal Corrales, Juan Antonio
BiomarkersCancer stem cellsExosomesMalignant melanomaMetabolomics
Palacios‐Ferrer, J. L., García‐Ortega, M. B., Gallardo‐Gómez, M., García, M. Á., Díaz, C., Boulaiz, H., ... & Marchal, J. A. (2020). Metabolomic profile of cancer stem cell‐derived exosomes from patients with malignant melanoma. Molecular Oncology. [doi:10.1002/1878-0261.12823]
PatrocinadorMICIU FPU15/03682 FPU15/02350; Ministerio de Ciencia, Innovación y Universidades (MICIU) MAT2015-62644.C2.2.R RTI2018-101309-BC2; Instituto de Salud Carlos III PIE16-00045; Junta de Andalucía SOMM17/6109/UGR (UCE-PP2017-3); European Union (EU) SOMM17/6109/UGR (UCE-PP2017-3); Chair 'Doctors Galera-Requena in cancer stem cell research' CMC-CTS963; Fundación MEDINA
Malignant melanoma (MM) is the most aggressive and life-threatening form of skin cancer. It is characterized by an extraordinary metastasis capacity and chemotherapy resistance, mainly due to melanoma cancer stem cells (CSCs). To date, there are no suitable clinical diagnostic, prognostic or predictive biomarkers for this neoplasia. Therefore, there is an urgent need for new MM biomarkers that enable early diagnosis and effective disease monitoring. Exosomes represent a novel source of biomarkers since they can be easily isolated from different body fluids. In this work, a primary patient-derived MM cell line enriched in CSCs was characterized by assessing the expression of specific markers and their stem-like properties. Exosomes derived from CSCs and serums from patients with MM were characterized, and their metabolomic profile was analysed by highresolution mass spectrometry (HRMS) following an untargeted approach and applying univariate and multivariate statistical analyses. The aim of this study was to search potential biomarkers for the diagnosis of this disease. Our results showed significant metabolomic differences in exosomes derived from MM CSCs compared with those from differentiated tumour cells and also in serum-derived exosomes from patients with MM compared to those from healthy controls. Interestingly, we identified similarities between structural lipids differentially expressed in CSC-derived exosomes and those derived from patients with MM such as the glycerophosphocholine PC 16:0/0:0. To our knowledge, this is the first metabolomic-based study aimed at characterizing exosomes derived from melanoma CSCs and patients’ serum in order to identify potential biomarkers for MM diagnosis. We conclude that metabolomic characterization of CSC-derived exosomes sets an open door to the discovery of clinically useful biomarkers in this neoplasia.